Doctor Hiroyoshi Yokoi
Fukuoka Sanno Hospital, Fukuoka (Japan)
Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices from Japan Post-Market Surveillance Study
Event: ESC Congress 2020
Topic: Intervention
Session: Lower Extremity Artery Revascularization in 2020
Comparison of long DAPT versus short DAPT in Japanese PCI patients based on healthcare information database
Event: ESC Congress 2018
Topic: Big Data Analysis
Session: Atrial fibrillation, stroke and cardiovascular risk
The Zilver PTX japanese post-market surveillance study of paclitaxel-eluting stents: 3 year results of the diabetic and in-stent restenosis subgroups
Event: ESC Congress 2017
Topic: Peripheral arterial disease
Session: Vascular diseases - 3
Impact of pioglitazone on cardiovascular events in patients with type-II diabetes mellitus after drug-eluting stent implantation
Event: ESC Congress 2016
Topic: Diabetes management
Session: Improving diabetes outcomes: beyond glucocentricity
Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 24-month results
Event: ESC Congress 2016
Topic: Percutaneous / endovascular treatment
Session: Peripheral interventions
Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices from Japan Post-Market Surveillance Study
Event: ESC Asia with APSC & AFC 2020
Topic: Intervention
Session: Abstract Programme
ESC 365 is supported by
